文献速递肿瘤 PET/CT核素与放射性配体治疗

开发FAPI四聚体以提高肿瘤摄取和FAPI放射性配体治疗疗效

Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy.
PubMed 文献 · J Nucl Med · 2023-06-15

研究基于FAPI-46设计合成FAPI四聚体,用68Ga、64Cu和177Lu标记,在HT-1080-FAP和U87MG荷瘤小鼠中评估体外FAP结合特性及体内药代动力学。结果显示四聚体较二聚体和FAPI-46具有更高的肿瘤摄取、更长的肿瘤滞留和更慢的清除,177Lu-FAPI四聚体在两种荷瘤小鼠中均观察到显著肿瘤抑制。

要点

  • FAPI四聚体在体外和体内均表现出高FAP结合亲和力和特异性。
  • 68Ga、64Cu和177Lu标记的FAPI四聚体较二聚体和FAPI-46具有更高肿瘤摄取、更长滞留和更慢清除。
  • 177Lu-FAPI四聚体在HT-1080-FAP和U87MG荷瘤小鼠中均观察到显著肿瘤抑制。

核心结论

  • FAPI四聚体具有满意的FAP结合亲和力和特异性以及良好的体内药代动力学,使其成为有前景的诊疗一体化放射性药物。
  • 177Lu-FAPI四聚体改善的肿瘤摄取和延长滞留为其在FAPI成像和放射性配体治疗中提供了优异特性。

研究设计与样本

  • 基于FAPI-46合成FAPI四聚体,并用68Ga、64Cu和177Lu进行放射性标记。
  • 采用竞争性细胞结合实验鉴定体外FAP结合特性。
  • 在HT-1080-FAP和U87MG荷瘤小鼠中进行小动物PET、SPECT和离体生物分布分析以评估药代动力学。
  • 两种肿瘤异种移植瘤接受177Lu-DOTA-4P(FAPI)4放射性配体治疗,并与177Lu-FAPI二聚体和单体比较抗肿瘤疗效。

主要发现

  • 68Ga-DOTA-4P(FAPI)4和177Lu-DOTA-4P(FAPI)4在磷酸盐缓冲液和胎牛血清中高度稳定。
  • 68Ga-、64Cu-和177Lu标记的FAPI四聚体在HT-1080-FAP肿瘤中较FAPI二聚体和FAPI-46表现出更高的肿瘤摄取、更长的肿瘤滞留和更慢的清除。
  • 177Lu-DOTA-4P(FAPI)4、177Lu-DOTA-2P(FAPI)2和177Lu-FAPI-46在HT-1080-FAP肿瘤中24小时的摄取(每克注射剂量百分比)分别为21.4 ± 1.7、17.1 ± 3.9和3.4 ± 0.7。
  • 68Ga-DOTA-4P(FAPI)4在U87MG肿瘤中的摄取约为68Ga-DOTA-2P(FAPI)2的2倍(SUVmean,0.72 ± 0.02 vs. 0.42 ± 0.03,P < 0.001),且超过68Ga-FAPI-46(0.16 ± 0.01,P < 0.001)的4倍。
  • 在放射性配体治疗研究中,177Lu-FAPI四聚体在HT-1080-FAP和U87MG荷瘤小鼠中均观察到显著肿瘤抑制。

关键数值与推荐

  • 177Lu-DOTA-4P(FAPI)4在HT-1080-FAP肿瘤中24小时摄取为21.4 ± 1.7 %ID/g。
  • 177Lu-DOTA-2P(FAPI)2在HT-1080-FAP肿瘤中24小时摄取为17.1 ± 3.9 %ID/g。
  • 177Lu-FAPI-46在HT-1080-FAP肿瘤中24小时摄取为3.4 ± 0.7 %ID/g。
  • 68Ga-DOTA-4P(FAPI)4在U87MG肿瘤中SUVmean为0.72 ± 0.02,68Ga-DOTA-2P(FAPI)2为0.42 ± 0.03(P < 0.001),68Ga-FAPI-46为0.16 ± 0.01(P < 0.001)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radiolabeled fibroblast activation protein (FAP) inhibitors (FAPIs) have shown promise as cancer diagnostic agents; however, the relatively short tumor retention of FAPIs may limit their application in radioligand therapy. In this paper, we report the design, synthesis, and evaluation of a FAPI tetramer. The aim of the study was to evaluate the tumor-targeting characteristics of radiolabeled FAPI multimers in vitro and in vivo, thereby providing information for the design of FAP-targeted radiopharmaceuticals based on the polyvalency principle. Methods: FAPI tetramers were synthesized on the basis of FAPI-46 and radiolabeled with 68Ga, 64Cu, and 177Lu. In vitro FAP-binding characteristics were identified using a competitive cell-binding experiment. To evaluate their pharmacokinetics, small-animal PET, SPECT, and ex vivo biodistribution analyses were performed on HT-1080-FAP and U87MG tumor-bearing mice. In addition, the 2 tumor xenografts received radioligand therapy with 177Lu-DOTA-4P(FAPI)4, and the antitumor efficacy of the 177Lu-FAPI tetramer was evaluated and compared with that of the 177Lu-FAPI dimer and monomer. Results: 68Ga-DOTA-4P(FAPI)4 and 177Lu-DOTA-4P(FAPI)4 were highly stable in phosphate-buffered saline and fetal bovine serum. The FAPI tetramer exhibited high FAP-binding affinity and specificity both in vitro and in vivo. 68Ga-, 64Cu-, and 177Lu-labeled FAPI tetramers exhibited higher tumor uptake, longer tumor retention, and slower clearance than FAPI dimers and FAPI-46 in HT-1080-FAP tumors. The uptake (percentage injected dose per gram) of 177Lu-DOTA-4P(FAPI)4, 177Lu-DOTA-2P(FAPI)2, and 177Lu-FAPI-46 in HT-1080-FAP tumors at 24 h was 21.4 ± 1.7, 17.1 ± 3.9, and 3.4 ± 0.7, respectively. Moreover, 68Ga-DOTA-4P(FAPI)4 uptake in U87MG tumors was approximately 2-fold the uptake of 68Ga-DOTA-2P(FAPI)2 (SUVmean, 0.72 ± 0.02 vs. 0.42 ± 0.03, P < 0.001) and more than 4-fold the uptake of 68Ga-FAPI-46 (0.16 ± 0.01, P < 0.001). In the radioligand therapy study, remarkable tumor suppression was observed with the 177Lu-FAPI tetramer in both HT-1080-FAP and U87MG tumor-bearing mice. Conclusion: The satisfactory FAP-binding affinity and specificity, as well as the favorable in vivo pharmacokinetics of the FAPI tetramer, make it a promising radiopharmaceutical for theranostic applications. Improved tumor uptake and prolonged retention of the 177Lu-FAPI tetramer resulted in excellent characteristics for FAPI imaging and radioligand therapy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Pang Y, Zhao L, Fang J, et al. Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy. J Nucl Med. 2023. PMID: 37321827. doi:10.2967/jnumed.123.265599

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。